Our Science – Pastan Website
Ira Pastan, M.D.
Selected Publications |
 |
| 1)
Wei H, Bera TK, Wayne AS, Xiang L, Colantonio S, Chertov O, Pastan I. A Modified Form of Diphthamide Causes Immunotoxin Resistance in a Lymphoma Cell Line with Deletion of WDR85. J. Biol. Chem. [Epub ahead of print], 2013. [Journal] |
|
| 2)
Weldon JE, Xiang L, Zhang J, Beers R, Walker DA, Onda M, Hassan R, Pastan I. A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity. Mol. Cancer Ther. 12: 48-57, 2013. [Journal] |
|
| 3)
Ueno T, Kobayashi N, Nakayama M, Takashima Y, Ohse T, Pastan I, Pippin JW, Shankland SJ, Uesugi N, Matsusaka T, Nagata M. Aberrant Notch1-dependent effects on glomerular parietal epithelial cells promotes collapsing focal segmental glomerulosclerosis with progressive podocyte loss. Kidney Int. [Epub ahead of print], 2013. [Journal] |
|
| 4)
Haso W, Lee DW, Shah NN, Stetler-Stevenson M, Yuan CM, Pastan IH, Dimitrov DS, Morgan RA, FitzGerald DJ, Barrett DM, Wayne AS, Mackall CL, Orentas RJ. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood. 121: 1165-74, 2013. [Journal] |
|
| 5)
Yamaguchi T, Danjo T, Pastan I, Hikida T, Nakanishi S. Distinct Roles of Segregated Transmission of the Septo-Habenular Pathway in Anxiety and Fear. Neuron. [Epub ahead of print], 2013. [Journal] |
|
| 6)
Chandramohan V, Bao X, Kato Kaneko M, Kato Y, Keir ST, Szafranski SE, Kuan CT, Pastan IH, Bigner DD. Recombinant anti-podoplanin (NZ-1) immunotoxin for the treatment of malignant brain tumors. Int. J. Cancer. 132: 2339-48, 2013. [Journal] |
|
| 7)
Choi BD, Kuan CT, Cai M, Archer GE, Mitchell DA, Gedeon PC, Sanchez-Perez L, Pastan I, Bigner DD, Sampson JH. Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma. Proc. Natl. Acad. Sci. U.S.A. 110: 270-5, 2013. [Journal] |
|
| 8)
Liu XF, Fitzgerald DJ, Pastan I. The insulin receptor negatively regulates the action of pseudomonas toxin-based immunotoxins and native pseudomonas toxin. Cancer Res. 73: 2281-8, 2013. [Journal] |
|
| 9)
Liu W, Onda M, Kim C, Xiang L, Weldon JE, Lee B, Pastan I. A recombinant immunotoxin engineered for increased stability by adding a disulfide bond has decreased immunogenicity. Protein Eng. Des. Sel. 25: 1-6, 2012. [Journal] |
|
| 10)
Liu XF, Bera TK, Kahue C, Escobar T, Fei Z, Raciti GA, Pastan I. ANKRD26 and Its Interacting Partners TRIO, GPS2, HMMR and DIPA Regulate Adipogenesis in 3T3-L1 Cells. PLoS ONE. 7: e38130, 2012. [Journal] |
|
| 11)
Pak Y, Zhang Y, Pastan I, Lee B. Antigen shedding may improve efficiencies for delivery of antibody-based anticancer agents in solid tumors. Cancer Res. 72: 3143-52, 2012. [Journal] |
|
| 12)
Liu X, Xiang L, Zhang Y, Becker KG, Bera TK, Pastan I. CAPC negatively regulates NF-kappaB activation and suppresses tumor growth and metastasis. Oncogene. 31: 1673-82, 2012. [Journal] |
|
| 13)
Ma J, Tang WK, Esser L, Pastan I, Xia D. Characterization of crystals of an antibody-recognition fragment of the cancer differentiation antigen mesothelin in complex with the therapeutic antibody MORAb-009. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 68: 950-3, 2012. [Journal] |
|
| 14)
Jang BS, Lee SM, Kim HS, Shin IS, Razjouyan F, Wang S, Yao Z, Pastan I, Dreher MR, Paik CH. Combined-modality radioimmunotherapy: synergistic effect of paclitaxel and additive effect of bevacizumab. Nucl. Med. Biol. 39: 472-83, 2012. [Journal] |
|
| 15)
Mehta AI, Choi BD, Ajay D, Raghavan R, Brady M, Friedman AH, Pastan I, Bigner DD, Sampson JH. Convection Enhanced Delivery of Macromolecules for Brain Tumors. Curr Drug Discov Technol. 9: 305-10, 2012. [Journal] |
|
| 16)
Tortorella LL, Pipalia NH, Mukherjee S, Pastan I, Fitzgerald D, Maxfield FR. Efficiency of immunotoxin cytotoxicity is modulated by the intracellular itinerary. PLoS ONE. 7: e47320, 2012. [Journal] |
|
| 17)
Mazor R, Vassall AN, Eberle JA, Beers R, Weldon JE, Venzon DJ, Tsang KY, Benhar I, Pastan I. Identification and elimination of an immunodominant T-cell epitope in recombinant immunotoxins based on Pseudomonas exotoxin A. Proc. Natl. Acad. Sci. U.S.A. 109: E3597-603, 2012. [Journal] |
|
| 18)
Wei H, Xiang L, Wayne AS, Chertov O, Fitzgerald DJ, Bera TK, Pastan I. Immunotoxin resistance via reversible methylation of the DPH4 promoter is a unique survival strategy. Proc. Natl. Acad. Sci. U.S.A. 109: 6898-903, 2012. [Journal] |
|
| 19)
Margalit M, Yogev L, Yavetz H, Lehavi O, Hauser R, Botchan A, Barda S, Levitin F, Weiss M, Pastan I, Wreschner DH, Paz G, Kleiman SE. Involvement of the prostate and testis expression (PATE)-like proteins in sperm-oocyte interaction. Hum. Reprod. 27: 1238-48, 2012. [Journal] |
|
| 20)
Matsusaka T, Niimura F, Shimizu A, Pastan I, Saito A, Kobori H, Nishiyama A, Ichikawa I. Liver Angiotensinogen Is the Primary Source of Renal Angiotensin II. J Am Soc Nephrol. 23: 1181-9, 2012. [Journal] |
|
| 21)
Zhang J, Qiu S, Zhang Y, Merino M, Fetsch P, Avital I, Filie A, Pastan I, Hassan R. Loss of mesothelin expression by mesothelioma cells grown in vitro determines sensitivity to anti-mesothelin immunotoxin SS1P. Anticancer Res. 32: 5151-8, 2012. [Journal] |
|
| 22)
Kelly RJ, Sharon E, Pastan I, Hassan R. Mesothelin-targeted agents in clinical trials and in preclinical development. Mol. Cancer Ther. 11: 517-25, 2012. [Journal] |
|
| 23)
Pastan I, Zhang Y. Modulating mesothelin shedding to improve therapy. Oncotarget. 3: 114-5, 2012. [Journal] |
|
| 24)
Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M, Fitzgerald DJ, Lechleider R, Pastan I. Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia. J. Clin. Oncol. 30: 1822-8, 2012. [Journal] |
|
| 25)
Bera TK, Walker DA, Sherins RJ, Pastan I. POTE protein, a cancer-testis antigen, is highly expressed in spermatids in human testis and is associated with apoptotic cells. Biochem. Biophys. Res. Commun. 417: 1271-4, 2012. [Journal] |
|
| 26)
Wang S, Shin IS, Hancock H, Jang B, Kim H, Lee SM, Zderic V, Frenkel V, Pastan I, Paik CH, Dreher MR. Pulsed high intensity focused ultrasound increases penetration and therapeutic efficacy of monoclonal antibodies in murine xenograft tumors. J Control Release. 162: 218-24, 2012. [Journal] |
|
| 27)
Ma J, Tang WK, Esser L, Pastan I, Xia D. Recognition of mesothelin by the therapeutic antibody MORAb-009: structural and mechanistic insights. J Biol Chem. 287: 33123-31, 2012. [Journal] |
|
| 28)
Liu W, Onda M, Lee B, Kreitman RJ, Hassan R, Xiang L, Pastan I. Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes. Proc. Natl. Acad. Sci. U.S.A. 109: 11782-7, 2012. [Journal] |
|
| 29)
Sharon E, Zhang J, Hollevoet K, Steinberg SM, Pastan I, Onda M, Gaedcke J, Ghadimi BM, Ried T, Hassan R. Serum mesothelin and megakaryocyte potentiating factor in pancreatic and biliary cancers. Clin. Chem. Lab. Med. 50: 721-5, 2012. [Journal] |
|
| 30)
Singh R, Zhang Y, Pastan I, Kreitman RJ. Synergistic antitumor activity of anti-CD25 recombinant immunotoxin LMB-2 with chemotherapy. Clin. Cancer Res. 18: 152-60, 2012. [Journal] |
|
| 31)
Baskar S, Wiestner A, Wilson WH, Pastan I, Rader C. Targeting malignant B cells with an immunotoxin against ROR1. MAbs. 4: 349-61, 2012. [Journal] |
|
| 32)
Biberacher V, Decker T, Oelsner M, Wagner M, Bogner C, Schmidt B, Kreitman RJ, Peschel C, Pastan I, Meyer Zum Büschenfelde C, Ringshausen I. The cytotoxicity of anti-CD22 immunotoxin is enhanced by bryostatin 1 in B-cell lymphomas through CD22 upregulation and PKC-beta depletion. Haematologica. 97: 771-9, 2012. [Journal] |
|
| 33)
Chandramohan V, Sampson JH, Pastan I, Bigner DD. Toxin-based targeted therapy for malignant brain tumors. Clin. Dev. Immunol. 2012: 480429, 2012. [Journal] |
|
| 34)
Weldon JE, Pastan I. A guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer. FEBS J. 278: 4683-700, 2011. [Journal] |
|
| 35)
Kuan CT, Wakiya K, Keir ST, Li J, Herndon JE, Pastan I, Bigner DD. Affinity-matured anti-glycoprotein NMB recombinant immunotoxins targeting malignant gliomas and melanomas. Int. J. Cancer. 129: 111-21, 2011. [Journal] |
|
| 36)
Fei Z, Bera TK, Liu X, Xiang L, Pastan I. ANKRD26 gene disruption enhances adipogenesis of mouse embryonic fibroblasts. J Biol Chem. 286: 27761-8, 2011. [Journal] |
|
| 37)
Kreitman RJ, Pastan I. Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin. Cancer Res. 17: 6398-405, 2011. [Journal] |
|
| 38)
Murata K, Imai M, Nakanishi S, Watanabe D, Pastan I, Kobayashi K, Nihira T, Mochizuki H, Yamada S, Mori K, Yamaguchi M. Compensation of Depleted Neuronal Subsets by New Neurons in a Local Area of the Adult Olfactory Bulb. J Neurosci. 31: 10540-10557, 2011. [Journal] |
|
| 39)
Zhang Y, Chertov O, Zhang J, Hassan R, Pastan I. Cytotoxic activity of immunotoxin SS1P is modulated by TACE-dependent mesothelin shedding. Cancer Res. 71: 5915-22, 2011. [Journal] |
|
| 40)
Shin IS, Lee S, Kim HS, Yao Z, Regino C, Sato N, Cheng KT, Hassan R, Campo MF, Albone EF, Choyke PL, Pastan I, Paik CH. Effect of chelator conjugation level and injection dose on tumor and organ uptake of (111)In-labeled MORAb-009, an anti-mesothelin antibody. Nucl Med Biol. 38: 1119-27, 2011. [Journal] |
|
| 41)
Fitzgerald DJ, Moskatel E, Ben-Josef G, Traini R, Tendler T, Sharma A, Antignani A, Mussai F, Wayne A, Kreitman RJ, Pastan I. Enhancing immunotoxin cell-killing activity via combination therapy with ABT-737. Leuk. Lymphoma. 52 Suppl 2: 79-81, 2011. [Journal] |
|
| 42)
Ackerman ME, Lai JI, Pastan I, Wittrup KD. Exploiting bias in a non-immune human antibody library to predict antigenicity. Protein Eng. Des. Sel. 24: 845-53, 2011. [Journal] |
|
| 43)
Matsusaka T, Kobayashi K, Kon V, Pastan I, Fogo AB, Ichikawa I. Glomerular sclerosis is prevented during urinary tract obstruction due to podocyte protection. Am. J. Physiol. Renal Physiol. 300: F792-800, 2011. [Journal] |
|
| 44)
Mehta AI, Choi BD, Raghavan R, Brady M, Friedman AH, Bigner DD, Pastan I, Sampson JH. Imaging of convection enhanced delivery of toxins in humans. Toxins (Basel). 3: 201-6, 2011. [Journal] |
|
| 45)
Pastan I, Onda M, Weldon J, Fitzgerald D, Kreitman R. Immunotoxins with decreased immunogenicity and improved activity. Leuk Lymphoma. 52 Suppl 2: 87-90, 2011. [Journal] |
|
| 46)
Du X, Xiang L, Mackall CL, Pastan I. Killing of Resistant Cancer Cells with Low Bak by a Combination of an Anti-mesothelin Immunotoxin and a TRAIL Receptor 2 Agonist Antibody. Clin Cancer Res. 17: 5926-34, 2011. [Journal] |
|
| 47)
Raciti GA, Bera TK, Gavrilova O, Pastan I. Partial inactivation of Ankrd26 causes diabetes with enhanced insulin responsiveness of adipose tissue in mice. Diabetologia. 54: 2911-22, 2011. [Journal] |
|
| 48)
Mossoba ME, Onda M, Taylor J, Massey PR, Treadwell S, Sharon E, Hassan R, Pastan I, Fowler D. Pentostatin Plus Cyclophosphamide Safely and Effectively Prevents Immunotoxin Immunogenicity in Murine Hosts. Clin Cancer Res. 17: 3697-705, 2011. [Journal] |
|
| 49)
Matsusaka T, Sandgren E, Shintani A, Kon V, Pastan I, Fogo AB, Ichikawa I. Podocyte Injury Damages Other Podocytes. J Am Soc Nephrol. 22: 1275-85, 2011. [Journal] |
|
| 50)
Onda M, Beers R, Xiang L, Lee B, Weldon JE, Kreitman RJ, Pastan I. Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes. Proc. Natl. Acad. Sci. U.S.A. 108: 5742-7, 2011. [Journal] |
|
| 51)
Kreitman RJ, Arons E, Stetler-Stevenson M, Fitzgerald DJ, Wilson WH, Pastan I. Recombinant immunotoxins and other therapies for relapsed/refractory hairy cell leukemia. Leuk. Lymphoma. 52 Suppl 2: 82-6, 2011. [Journal] |
|
| 52)
Kawa S, Onda M, Ho M, Kreitman RJ, Bera TK, Pastan I. The improvement of an anti-CD22 immunotoxin: conversion to single-chain and disulfide stabilized form and affinity maturation by alanine scan. MAbs. 3: 479-86, 2011. [Journal] |
|
| 53)
FitzGerald DJ, Wayne AS, Kreitman RJ, Pastan I. Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates. Cancer Res. 71: 6300-9, 2011. [Journal] |
|
| 54)
Zhang Y, Hansen JK, Xiang L, Kawa S, Onda M, Ho M, Hassan R, Pastan I. A flow cytometry method to quantitate internalized immunotoxins shows that taxol synergistically increases cellular immunotoxins uptake. Cancer Res. 70: 1082-9, 2010. [Journal] |
|
| 55)
Ho M, Feng M, Fisher RJ, Rader C, Pastan I. A novel high affinity human monoclonal antibody to mesothelin. Int J Cancer. 128: 2020-30, 2010. [Journal] |
|
| 56)
Hansen JK, Weldon JE, Xiang L, Beers R, Onda M, Pastan I. A recombinant immunotoxin targeting CD22 with low immunogenicity, low nonspecific toxicity, and high antitumor activity in mice. J. Immunother. 33: 297-304, 2010. [Journal] |
|
| 57)
Matsusaka T, Asano T, Niimura F, Kinomura M, Shimizu A, Shintani A, Pastan I, Fogo AB, Ichikawa I. Angiotensin receptor blocker protection against podocyte-induced sclerosis is podocyte angiotensin II type 1 receptor-independent. Hypertension. 55: 967-73, 2010. [Journal] |
|
| 58)
Wayne AS, Kreitman RJ, Findley HW, Lew G, Delbrook C, Steinberg SM, Stetler-Stevenson M, Fitzgerald DJ, Pastan I. Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial. Clin. Cancer Res. 16: 1894-903, 2010. [Journal] |
|
| 59)
Ding D, Kanaly CW, Bigner DD, Cummings TJ, Herndon JE, Pastan I, Raghavan R, Sampson JH. Convection-enhanced delivery of free gadolinium with the recombinant immunotoxin MR1-1. J. Neurooncol. 98: 1-7, 2010. [Journal] |
|
| 60)
Mussai F, Campana D, Bhojwani D, Stetler-Stevenson M, Steinberg SM, Wayne AS, Pastan I. Cytotoxicity of the anti-CD22 immunotoxin HA22 (CAT-8015) against paediatric acute lymphoblastic leukaemia. Br. J. Haematol. 150: 352-8, 2010. [Journal] |
|
| 61)
Bogner C, Dechow T, Ringshausen I, Wagner M, Oelsner M, Lutzny G, Licht T, Peschel C, Pastan I, Kreitman RJ, Decker T. Immunotoxin BL22 induces apoptosis in mantle cell lymphoma (MCL) cells dependent on Bcl-2 expression. Br. J. Haematol. 148: 99-109, 2010. [Journal] |
|
| 62)
Berger EA, Pastan I. Immunotoxin complementation of HAART to deplete persisting HIV-infected cell reservoirs. PLoS Pathog. 6: e1000803, 2010. [Journal] |
|
| 63)
Hassan R, Schweizer C, Lu KF, Schuler B, Remaley AT, Weil SC, Pastan I. Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy. Lung Cancer. 68: 455-9, 2010. [Journal] |
|
| 64)
Luther N, Cheung NK, Souliopoulos EP, Karempelas I, Bassiri D, Edgar MA, Guo HF, Pastan I, Gutin PH, Souweidane MM. Interstitial infusion of glioma-targeted recombinant immunotoxin 8H9scFv-PE38. Mol. Cancer Ther. 9: 1039-46, 2010. [Journal] |
|
| 65)
Cereda V, Poole DJ, Palena C, Das S, Bera TK, Remondo C, Gulley JL, Arlen PM, Yokokawa J, Pastan I, Schlom J, Tsang KY. New gene expressed in prostate: a potential target for T cell-mediated prostate cancer immunotherapy. Cancer Immunol. Immunother. 59: 63-71, 2010. [Journal] |
|
| 66)
Hassan R, Cohen SJ, Phillips M, Pastan I, Sharon E, Kelly RJ, Schweizer C, Weil S, Laheru D. Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers. Clin. Cancer Res. 16: 6132-8, 2010. [Journal] |
|
| 67)
Du X, Youle RJ, FitzGerald DJ, Pastan I. Pseudomonas exotoxin A-mediated apoptosis is Bak dependent and preceded by the degradation of Mcl-1. Mol. Cell. Biol. 30: 3444-52, 2010. [Journal] |
|
| 68)
Feng Y, Xiao X, Zhu Z, Streaker E, Ho M, Pastan I, Dimitrov DS. A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity. Mol. Cancer Ther. 8: 1113-8, 2009. [Journal] |
|
| 69)
Liu XF, Bera TK, Liu LJ, Pastan I. A primate-specific POTE-actin fusion protein plays a role in apoptosis. Apoptosis. 14: 1237-44, 2009. [Journal] |
|
| 70)
Weldon JE, Xiang L, Chertov O, Margulies I, Kreitman RJ, FitzGerald DJ, Pastan I. A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity. Blood. 113: 3792-800, 2009. [Journal] |
|
| 71)
Hahn Y, Kim DS, Pastan IH, Lee B. Anoctamin and transmembrane channel-like proteins are evolutionarily related. Int. J. Mol. Med. 24: 51-5, 2009. [Journal] |
|
| 72)
Kreitman RJ, Fitzgerald DJ, Pastan I. Approach to the patient after relapse of hairy cell leukemia. Leuk. Lymphoma. 50 Suppl 1: 32-7, 2009. [Journal] |
|
| 73)
Alderson RF, Kreitman RJ, Chen T, Yeung P, Herbst R, Fox JA, Pastan I. CAT-8015: a second-generation pseudomonas exotoxin A-based immunotherapy targeting CD22-expressing hematologic malignancies. Clin. Cancer Res. 15: 832-9, 2009. [Journal] |
|
| 74)
Carpenito C, Milone MC, Hassan R, Simonet JC, Lakhal M, Suhoski MM, Varela-Rohena A, Haines KM, Heitjan DF, Albelda SM, Carroll RG, Riley JL, Pastan I, June CH. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc. Natl. Acad. Sci. U.S.A. 106: 3360-5, 2009. [Journal] |
|
| 75)
Ho M, Pastan I. Display and selection of scFv antibodies on HEK-293T cells. Methods Mol. Biol. 562: 99-113, 2009. [Journal] |
|
| 76)
Nagata S, Ise T, Pastan I. Fc receptor-like 3 protein expressed on IL-2 nonresponsive subset of human regulatory T cells. J. Immunol. 182: 7518-26, 2009. [Journal] |
|
| 77)
Xiao X, Ho M, Zhu Z, Pastan I, Dimitrov DS. Identification and characterization of fully human anti-CD22 monoclonal antibodies. MAbs. 1: 297-303, 2009. [Journal] |
|
| 78)
Ho M, Pastan I. In vitro antibody affinity maturation targeting germline hotspots. Methods Mol. Biol. 525: 293-308, xiv, 2009. [Journal] |
|
| 79)
Ho M, Pastan I. Mammalian cell display for antibody engineering. Methods Mol. Biol. 525: 337-52, xiv, 2009. [Journal] |
|
| 80)
Anaganti S, Hansen JK, Ha D, Hahn Y, Chertov O, Pastan I, Bera TK. Non-AUG translational initiation of a short CAPC transcript generating protein isoform. Biochem. Biophys. Res. Commun. 380: 508-13, 2009. [Journal] |
|
| 81)
Kreitman RJ, Hassan R, Fitzgerald DJ, Pastan I. Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Clin. Cancer Res. 15: 5274-9, 2009. [Journal] |
|
| 82)
Kreitman RJ, Stetler-Stevenson M, Margulies I, Noel P, Fitzgerald DJ, Wilson WH, Pastan I. Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J. Clin. Oncol. 27: 2983-90, 2009. [Journal] |
|
| 83)
Nagata S, Pastan I. Removal of B cell epitopes as a practical approach for reducing the immunogenicity of foreign protein-based therapeutics. Adv. Drug Deliv. Rev. 61: 977-85, 2009. [Journal] |
|
| 84)
Bera TK, Liu XF, Yamada M, Gavrilova O, Mezey E, Tessarollo L, Anver M, Hahn Y, Lee B, Pastan I. A model for obesity and gigantism due to disruption of the Ankrd26 gene. Proc. Natl. Acad. Sci. U.S.A. 105: 270-5, 2008. [Journal] |
|
| 85)
Onda M, Beers R, Xiang L, Nagata S, Wang QC, Pastan I. An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes. Proc. Natl. Acad. Sci. U.S.A. 105: 11311-6, 2008. [Journal] |
|
| 86)
Zhang Y, Pastan I. High shed antigen levels within tumors, an additional barrier to immunoconjugate therapy. Clin. Cancer Res. 14: 7981-7986, 2008. Full Text Article. [Journal] |
|
| 87)
Zhang Y, Xiang L, Hassan R, Pastan I. Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors. Proc. Natl. Acad. Sci. U.S.A. 104: 17099-104, 2007. [Journal] |
|
| 88)
Hassan R, Bullock S, Premkumar A, Kreitman R, Kindler H, Willingham M, Pastan I. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus intravenous infusion to patients with mesothelin expressing mesothelioma, ovarian and pancreatic cancers. Clin Cancer Res. 13: 5144-5149, 2007. [Journal] |
|
| 89)
Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ. Immunotoxin therapy of cancer. Nat. Rev. Cancer. 6: 559-65, 2006. [Journal] |
|
| 90)
Pastan I. An NIH career: from bedside to basic research and back. J. Biol. Chem. 280: 18553-7, 2005. [Journal] |
|
| 91)
Kreitman RJ, Wilson WH, Bergeron K, Raggio M, Stetler-Stevenson M, FitzGerald DJ, Pastan I. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N. Engl. J. Med. 345: 241-7, 2001. [Journal] |
|
| Click Here to View Collapsed Bibliography. |
This page was last updated on 4/26/2013.
